<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
  xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
  xmlns:atom="http://www.w3.org/2005/Atom"
  xmlns:content="http://purl.org/rss/1.0/modules/content/">

  <channel>
    <title>REWIRED: THE IBOGAINE EXPERIENCE</title>
    <link>https://theibogainstitute.org</link>
    <language>en-us</language>
    <description>Rewired: The Ibogaine Experience shares real stories from patients and families who have experienced ibogaine therapy for PTSD, addiction, Parkinson's disease, and other conditions.
    
Brought to you by IBOGA Wellness Institute.
    
Every week, you'll hear honest conversations about struggle, recovery, and what happens after treatment. Veterans with PTSD, people overcoming addiction, patients with Parkinson's experiencing symptom improvements, and the family members who supported them through the decision.
    
These are authentic stories backed by research. No false promises. No wellness industry marketing. Just real people sharing what worked when traditional treatments failed.
    
If you're researching options for someone you love, or seeking answers for yourself, you're not alone.
    
New episodes every week. Real stories. Real outcomes. Real hope.
    
Learn more: https://theibogainstitute.org</description>

    <!-- Set this to the final public URL where THIS RSS XML is hosted -->
    <atom:link href="https://raw.githubusercontent.com/aidatamanagement/Iboga_Podcast/main/Rewired.xml" rel="self" type="application/rss+xml"/>

    <!-- Recommended metadata -->
    <lastBuildDate>Wed, 03 Dec 2025 10:15:00 -0500</lastBuildDate>
    <itunes:type>episodic</itunes:type>

    <!-- Spotify reads iTunes podcast tags -->
    <itunes:author>Sarah Mitchell</itunes:author>
    <itunes:summary>Sarah Mitchell has personal experience researching treatments for a loved one at 2am. She knows what it's like to be exhausted, hopeful, and trying to separate science from marketing. After seeing the real results ibogaine offers, Sarah brings you the research and shares authentic experiences from people who have walked this path.
Sarah speaks to you as a peer, not an expert. She's been where you are.</itunes:summary>
    <itunes:explicit>false</itunes:explicit>

    <itunes:owner>
      <itunes:name>Shubakar Poda</itunes:name>
      <itunes:email>contactus@theibogainstitute.org</itunes:email>
    </itunes:owner>

    <itunes:category text="Technology"/>

    <!-- Prefer hosting your own cover art long-term, but this URL is syntactically fine -->
    <itunes:image href="https://oimqzyfmglyhljjuboek.supabase.co/storage/v1/object/public/IBoga_Podcast_Files/Rewired%20by%20Iboga%20Wellness%20Institute%20Main%20banner.jpg"/>

    <!-- Optional nice-to-haves -->
    <itunes:subtitle>Supabase-hosted podcast feed test</itunes:subtitle>
    <itunes:keywords>supabase, podcast, testing, aidm</itunes:keywords>



  
 
    

  
  
    <item>
      <title><![CDATA[The GDNF Connection: How Ibogaine Triggers Brain Repair in Parkinson's Disease]]></title>
      <itunes:image href="https://oimqzyfmglyhljjuboek.supabase.co/storage/v1/object/public/IBoga_Podcast_Files/TheGDNFConnectionHowIbogaineTriggersBrainRepairinParkinsonsDisease_Episode_Image.jpeg" />
      <description><![CDATA[Research indicates that a specific dose of ibogaine can increase GDNF, a critical brain repair protein, by up to twelve-fold in the Ventral Tegmental Area and six-fold in the Substantia Nigra—the very regions ravaged by Parkinson's disease. These findings are foundational to the profound changes our clients experience.

This scientific discovery translates into genuine hope and significant improvements for millions. Just like Michael, a 62-year-old former engineer who battled Parkinson's for a decade, facing increasing tremors and stiffness that stole his independence, clients are discovering a path forward. He came to us after conventional treatments offered little more than symptom management, desperate for an alternative.

Parkinson's affects over a million people in the U.S. alone, a number projected to increase by 60% in the next two decades. It's the second most common neurodegenerative disease after Alzheimer's. For too long, the conventional wisdom has been that Parkinson's is irreversible, a progressive decline that can only be managed, not halted or reversed. Standard treatments like Levodopa offer temporary relief, but often come with debilitating side effects and diminish in efficacy over time, leaving clients and their families desperate for something more.

The core problem in Parkinson's is the loss of dopamine-producing neurons. This is where the GDNF connection becomes so pivotal. GDNF stands for Glial Cell Line-Derived Neurotrophic Factor, and it's a naturally occurring protein that acts like a guardian and restorer for these vital dopamine neurons. It helps them survive, thrive, and even regenerate. Previous attempts to deliver GDNF directly to the brain were invasive and inconsistent, using gene therapy or direct brain infusions that often failed to provide consistent, widespread benefit.

The breakthrough is that ibogaine naturally stimulates the brain's own GDNF production. Studies show that a specific dosage of ibogaine leads to a twelve-fold increase of GDNF in the Ventral Tegmental Area and a six-fold increase in the Substantia Nigra. These are precisely the brain regions where dopamine neurons degenerate in Parkinson's. This means ibogaine offers a non-invasive way to boost the brain's inherent protective and restorative mechanisms, directly addressing the underlying neurological damage, not just masking symptoms. Ibogaine crosses the blood-brain barrier and activates cellular pathways that upregulate GDNF expression, essentially telling the brain to start repairing itself.

The clinical evidence is building. Ambio Life Sciences launched one of the world's first clinical ibogaine neuroregenerative programs, treating clients with conditions like Parkinson's, MS, and essential tremor. One specific retreat program with thirty Parkinson's clients reported an average of 70% reduction in Parkinson's severity by the end of their fourteen-day program. What's truly remarkable is the rapid response; many clients experienced a 50% or more symptom reduction within just three to four days. Our client Michael experienced this firsthand. His tremors, which had made daily tasks almost impossible, significantly subsided, and his mobility improved noticeably within the first week of his treatment. Beyond motor symptoms like tremor and rigidity, clients report improvements in non-motor symptoms such as eyesight, neuropathic pain, sleep quality, anxiety, and mood. The sustained benefit comes, in part, from noribogaine, a metabolite of ibogaine that remains active in the body for months, continuing to provide therapeutic effects and neuroplasticity.

Ibogaine's effectiveness where single-mechanism drugs often fail stems from its multi-system approach. First, it directly modulates the dopamine system, addressing the core deficit in Parkinson's. Second, it has powerful neuroprotective properties, potentially slowing or even reversing disease progression. Third, it enhances neuroplasticity, helping the brain form new, healthy pathways. And fourth, it offers anti-inflammatory effects, reducing neuroinflammation which is increasingly understood to play a role in Parkinson's.

For clients with Parkinson's, the treatment protocol is carefully optimized to account for physical challenges. This can involve a specific loading dose of ibogaine, followed by microdosing for maintenance, which uses very small amounts of the substance to sustain benefits with minimal psychoactive effects. Throughout this, safety is paramount. We adhere to rigorous medical supervision and protocols, including 24/7 medical monitoring, comprehensive cardiac surveillance, and co-administration of magnesium for heart protection. This meticulous approach ensures that a powerful compound is delivered as breakthrough medicine.

For clients like Michael, this means hope where hope was once lost. While we are not claiming a cure, we are seeing measurable, significant improvements in what was previously considered an irreversible condition. This shift from managing decline to supporting regeneration is profound. Ongoing research at institutions like Dalhousie University, alongside pharmaceutical development of compounds like CKBR-12, continues to validate ibogaine's potential. Provisional patents are even being filed for methods that provide rapid symptom reduction in neurodegenerative disorders. For millions affected by Parkinson's, ibogaine offers not just symptom management, but genuine hope for a better quality of life.]]></description>
      <content:encoded><![CDATA[Research indicates that a specific dose of ibogaine can increase GDNF, a critical brain repair protein, by up to twelve-fold in the Ventral Tegmental Area and six-fold in the Substantia Nigra—the very regions ravaged by Parkinson's disease. These findings are foundational to the profound changes our clients experience.

This scientific discovery translates into genuine hope and significant improvements for millions. Just like Michael, a 62-year-old former engineer who battled Parkinson's for a decade, facing increasing tremors and stiffness that stole his independence, clients are discovering a path forward. He came to us after conventional treatments offered little more than symptom management, desperate for an alternative.

Parkinson's affects over a million people in the U.S. alone, a number projected to increase by 60% in the next two decades. It's the second most common neurodegenerative disease after Alzheimer's. For too long, the conventional wisdom has been that Parkinson's is irreversible, a progressive decline that can only be managed, not halted or reversed. Standard treatments like Levodopa offer temporary relief, but often come with debilitating side effects and diminish in efficacy over time, leaving clients and their families desperate for something more.

The core problem in Parkinson's is the loss of dopamine-producing neurons. This is where the GDNF connection becomes so pivotal. GDNF stands for Glial Cell Line-Derived Neurotrophic Factor, and it's a naturally occurring protein that acts like a guardian and restorer for these vital dopamine neurons. It helps them survive, thrive, and even regenerate. Previous attempts to deliver GDNF directly to the brain were invasive and inconsistent, using gene therapy or direct brain infusions that often failed to provide consistent, widespread benefit.

The breakthrough is that ibogaine naturally stimulates the brain's own GDNF production. Studies show that a specific dosage of ibogaine leads to a twelve-fold increase of GDNF in the Ventral Tegmental Area and a six-fold increase in the Substantia Nigra. These are precisely the brain regions where dopamine neurons degenerate in Parkinson's. This means ibogaine offers a non-invasive way to boost the brain's inherent protective and restorative mechanisms, directly addressing the underlying neurological damage, not just masking symptoms. Ibogaine crosses the blood-brain barrier and activates cellular pathways that upregulate GDNF expression, essentially telling the brain to start repairing itself.

The clinical evidence is building. Ambio Life Sciences launched one of the world's first clinical ibogaine neuroregenerative programs, treating clients with conditions like Parkinson's, MS, and essential tremor. One specific retreat program with thirty Parkinson's clients reported an average of 70% reduction in Parkinson's severity by the end of their fourteen-day program. What's truly remarkable is the rapid response; many clients experienced a 50% or more symptom reduction within just three to four days. Our client Michael experienced this firsthand. His tremors, which had made daily tasks almost impossible, significantly subsided, and his mobility improved noticeably within the first week of his treatment. Beyond motor symptoms like tremor and rigidity, clients report improvements in non-motor symptoms such as eyesight, neuropathic pain, sleep quality, anxiety, and mood. The sustained benefit comes, in part, from noribogaine, a metabolite of ibogaine that remains active in the body for months, continuing to provide therapeutic effects and neuroplasticity.

Ibogaine's effectiveness where single-mechanism drugs often fail stems from its multi-system approach. First, it directly modulates the dopamine system, addressing the core deficit in Parkinson's. Second, it has powerful neuroprotective properties, potentially slowing or even reversing disease progression. Third, it enhances neuroplasticity, helping the brain form new, healthy pathways. And fourth, it offers anti-inflammatory effects, reducing neuroinflammation which is increasingly understood to play a role in Parkinson's.

For clients with Parkinson's, the treatment protocol is carefully optimized to account for physical challenges. This can involve a specific loading dose of ibogaine, followed by microdosing for maintenance, which uses very small amounts of the substance to sustain benefits with minimal psychoactive effects. Throughout this, safety is paramount. We adhere to rigorous medical supervision and protocols, including 24/7 medical monitoring, comprehensive cardiac surveillance, and co-administration of magnesium for heart protection. This meticulous approach ensures that a powerful compound is delivered as breakthrough medicine.

For clients like Michael, this means hope where hope was once lost. While we are not claiming a cure, we are seeing measurable, significant improvements in what was previously considered an irreversible condition. This shift from managing decline to supporting regeneration is profound. Ongoing research at institutions like Dalhousie University, alongside pharmaceutical development of compounds like CKBR-12, continues to validate ibogaine's potential. Provisional patents are even being filed for methods that provide rapid symptom reduction in neurodegenerative disorders. For millions affected by Parkinson's, ibogaine offers not just symptom management, but genuine hope for a better quality of life.]]></content:encoded>
      <guid isPermaLink="false">TheGDNFConnectionHowIbogaineTriggersBrainRepairinParkinsonsDisease</guid>
      <pubDate>Mon, 15 Dec 2025 17:27:10 GMT</pubDate>
      <enclosure
        url="https://oimqzyfmglyhljjuboek.supabase.co/storage/v1/object/public/IBoga_Podcast_Files/TheGDNFConnectionHowIbogaineTriggersBrainRepairinParkinsonsDisease.mp3"
        length="12345678"
        type="audio/mpeg" />
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>


  
    <item>
      <title><![CDATA[The Pain Reset: Research on Ibogaine's Unprecedented Relief for Chronic Neuropathic Pain]]></title>
      <itunes:image href="https://oimqzyfmglyhljjuboek.supabase.co/storage/v1/object/public/IBoga_Podcast_Files/ThePainResetResearchonIbogainesUnprecedentedReliefforChronicNeuropathicPain_Episode_Image.jpeg" />
      <description><![CDATA[A groundbreaking case study documented the complete elimination of severe, intractable neuropathic pain in a client who had suffered for 20 years. This individual, battling pain from a brachial plexus nerve root avulsion—one of the most challenging pain conditions known—experienced a 100% reduction in their DN4 pain scores after ibogaine treatment, with improvements sustained long-term.

That research represents an extraordinary beacon of hope for millions. Today, you'll hear about a client whose life was transformed after decades of suffering. He faced the prospect of a radical DREZ surgery, a procedure that would essentially burn his nerves, when he discovered ibogaine. His story unveils how ibogaine offers a unique pathway to truly reset the pain response, addressing what conventional medicine often cannot.

Let's call him Mark, a 53-year-old man whose life took an agonizing turn two decades ago after a devastating motorcycle accident. The crash left him with a brachial plexus nerve root avulsion, a severe injury where nerves are torn from the spinal cord itself.

For twenty years, Mark lived with unrelenting, toxic nerve pain. It wasn't just physical; it was an electric current, a constant burning, shooting sensation that permeated every moment of his day. This wasn't the kind of pain that heals; it was neuropathic pain, caused by malfunctioning nerves themselves, persistently firing long after the initial injury. It’s the kind of pain seen in diabetic neuropathy, phantom limb syndrome, or trigeminal neuralgia, and it persists long after any initial tissue injury.

Mark’s journey through conventional medicine was a relentless cycle of disappointment. He tried everything: gabapentin, tramadol, oxycontin, methadone, multiple types of antidepressants, calcium channel anticonvulsants, mirror therapy, mindfulness, and even expensive fetal stem cell treatments. Opioids often proved ineffective for his specific type of nerve pain, and other medications like gabapentin offered only modest benefit, often with cognitive side effects. Nothing provided sustainable relief. His options had dwindled to one last, drastic measure: DREZ surgery, which involves burning the damaged nerves—a procedure with significant risks and no guarantee of success.

Desperate for any alternative, Mark started researching. He stumbled upon anecdotal reports and then scientific papers about ibogaine's potential, not just for addiction, but for chronic pain. The idea of a 'neurological reset' resonated with him, a stark contrast to the symptom management he’d been offered for decades.

At Iboga Wellness Institute, we emphasize that safety is paramount. Mark underwent thorough medical screening, including comprehensive cardiac evaluations. During his treatment, he was under 24/7 medical monitoring, with continuous cardiac surveillance and magnesium co-administration, ensuring a secure environment for this powerful therapy.

Ibogaine works uniquely on the brain to address pain. One key way it tackles neuropathic pain is by acting as an NMDA receptor antagonist. Imagine your nervous system becoming 'wound up' over time, with pain signals amplifying themselves, making the nervous system increasingly sensitive. Ibogaine helps to interrupt this amplification cycle, effectively hitting a reset button, much like ketamine in some respects, but with different downstream effects.

Beyond that, ibogaine has a special affinity for sigma-2 receptors, which are known to modulate pain perception, especially at the spinal cord level. Compounds with similar sigma action have shown promise in reducing neuropathic pain in animal models, suggesting ibogaine can influence pain signals at multiple levels.

But what truly sets ibogaine apart is its ability to stimulate neurotrophic factors, like Glial Cell Line-Derived Neurotrophic Factor, or GDNF. GDNF has been shown to prevent and even reverse sensory abnormalities in neuropathic pain models. This means ibogaine isn't just masking pain; it's actively promoting the repair of damaged nerve circuits, a concept almost revolutionary in pain management. This is neurological transformation, not just symptom management.

Mark underwent both a flood dose and saturation protocols. He described the initial phase not as pain, but as an "unraveling of chaos"—a profound experience where the constant sensation of pain seemed to dissolve.

The results were nothing short of remarkable. Quantitatively, his DN4 pain scores—a clinical measure of neuropathic pain—dropped by 100%. For the first time in twenty years, Mark experienced moments, then sustained periods, without the burning, shooting agony. His improvements were sustained throughout his initial four treatment phases. To maintain this newfound relief, he followed an outpatient maintenance protocol, with adjusted daily microdoses of ibogaine, ranging from 40 to 250 milligrams, tailored to his needs.

Today, months later, Mark continues to manage his pain with this protocol, having regained a quality of life he thought was permanently lost. His case, published as a groundbreaking report, demonstrated that for one of the most intractable pain conditions, ibogaine offered a path to not just manage, but to effectively eliminate the pain.

This isn't an isolated mechanism. Ibogaine derivatives, known as ibogalogs or iboga-analogues, are also being researched for their pain-relieving properties without the intense psychoactive effects. Studies show these compounds can decrease mechanical pain sensitivity and reduce inflammatory markers, such as Substance P, CGRP, and pro-inflammatory cytokines like IL-6 and TNF-α. They can even improve restricted locomotor activity and reduce anxiety in animal models of chronic pain. This points to a future where potentially gentler, non-hallucinogenic options could also harness ibogaine’s neurobiological benefits.

The potential implications extend far beyond a single case. Think about conditions like fibromyalgia, with its widespread pain, fatigue, and cognitive difficulties. Ibogaine’s ability to influence neurotrophic factors, calm NMDA receptors, and reduce inflammation could directly address the pathways implicated in such chronic, diffuse pain syndromes.

For clients struggling with both chronic pain and opioid dependence, ibogaine offers a unique advantage. It can significantly lower opioid tolerance, allowing for a reduction or even cessation of medication while simultaneously improving pain control. It essentially helps restore natural opioid signaling through its sigma-2 receptor affinity, breaking the cycle of both dependence and unmanaged pain. We've seen clients successfully manage hydromorphone, oxycodone, and morphine dependence using ibogaine microdosing protocols for pain.

At Iboga Wellness Institute, our protocols for pain management are highly individualized. They often involve an initial flood dose to achieve that profound neurological reset, followed by extended microdosing or saturation protocols to maintain therapeutic noribogaine levels and support the ongoing healing process. It’s about empowering the body and brain to heal, rather than just endlessly suppressing symptoms, offering a unique avenue for those who have exhausted all other conventional options.]]></description>
      <content:encoded><![CDATA[A groundbreaking case study documented the complete elimination of severe, intractable neuropathic pain in a client who had suffered for 20 years. This individual, battling pain from a brachial plexus nerve root avulsion—one of the most challenging pain conditions known—experienced a 100% reduction in their DN4 pain scores after ibogaine treatment, with improvements sustained long-term.

That research represents an extraordinary beacon of hope for millions. Today, you'll hear about a client whose life was transformed after decades of suffering. He faced the prospect of a radical DREZ surgery, a procedure that would essentially burn his nerves, when he discovered ibogaine. His story unveils how ibogaine offers a unique pathway to truly reset the pain response, addressing what conventional medicine often cannot.

Let's call him Mark, a 53-year-old man whose life took an agonizing turn two decades ago after a devastating motorcycle accident. The crash left him with a brachial plexus nerve root avulsion, a severe injury where nerves are torn from the spinal cord itself.

For twenty years, Mark lived with unrelenting, toxic nerve pain. It wasn't just physical; it was an electric current, a constant burning, shooting sensation that permeated every moment of his day. This wasn't the kind of pain that heals; it was neuropathic pain, caused by malfunctioning nerves themselves, persistently firing long after the initial injury. It’s the kind of pain seen in diabetic neuropathy, phantom limb syndrome, or trigeminal neuralgia, and it persists long after any initial tissue injury.

Mark’s journey through conventional medicine was a relentless cycle of disappointment. He tried everything: gabapentin, tramadol, oxycontin, methadone, multiple types of antidepressants, calcium channel anticonvulsants, mirror therapy, mindfulness, and even expensive fetal stem cell treatments. Opioids often proved ineffective for his specific type of nerve pain, and other medications like gabapentin offered only modest benefit, often with cognitive side effects. Nothing provided sustainable relief. His options had dwindled to one last, drastic measure: DREZ surgery, which involves burning the damaged nerves—a procedure with significant risks and no guarantee of success.

Desperate for any alternative, Mark started researching. He stumbled upon anecdotal reports and then scientific papers about ibogaine's potential, not just for addiction, but for chronic pain. The idea of a 'neurological reset' resonated with him, a stark contrast to the symptom management he’d been offered for decades.

At Iboga Wellness Institute, we emphasize that safety is paramount. Mark underwent thorough medical screening, including comprehensive cardiac evaluations. During his treatment, he was under 24/7 medical monitoring, with continuous cardiac surveillance and magnesium co-administration, ensuring a secure environment for this powerful therapy.

Ibogaine works uniquely on the brain to address pain. One key way it tackles neuropathic pain is by acting as an NMDA receptor antagonist. Imagine your nervous system becoming 'wound up' over time, with pain signals amplifying themselves, making the nervous system increasingly sensitive. Ibogaine helps to interrupt this amplification cycle, effectively hitting a reset button, much like ketamine in some respects, but with different downstream effects.

Beyond that, ibogaine has a special affinity for sigma-2 receptors, which are known to modulate pain perception, especially at the spinal cord level. Compounds with similar sigma action have shown promise in reducing neuropathic pain in animal models, suggesting ibogaine can influence pain signals at multiple levels.

But what truly sets ibogaine apart is its ability to stimulate neurotrophic factors, like Glial Cell Line-Derived Neurotrophic Factor, or GDNF. GDNF has been shown to prevent and even reverse sensory abnormalities in neuropathic pain models. This means ibogaine isn't just masking pain; it's actively promoting the repair of damaged nerve circuits, a concept almost revolutionary in pain management. This is neurological transformation, not just symptom management.

Mark underwent both a flood dose and saturation protocols. He described the initial phase not as pain, but as an "unraveling of chaos"—a profound experience where the constant sensation of pain seemed to dissolve.

The results were nothing short of remarkable. Quantitatively, his DN4 pain scores—a clinical measure of neuropathic pain—dropped by 100%. For the first time in twenty years, Mark experienced moments, then sustained periods, without the burning, shooting agony. His improvements were sustained throughout his initial four treatment phases. To maintain this newfound relief, he followed an outpatient maintenance protocol, with adjusted daily microdoses of ibogaine, ranging from 40 to 250 milligrams, tailored to his needs.

Today, months later, Mark continues to manage his pain with this protocol, having regained a quality of life he thought was permanently lost. His case, published as a groundbreaking report, demonstrated that for one of the most intractable pain conditions, ibogaine offered a path to not just manage, but to effectively eliminate the pain.

This isn't an isolated mechanism. Ibogaine derivatives, known as ibogalogs or iboga-analogues, are also being researched for their pain-relieving properties without the intense psychoactive effects. Studies show these compounds can decrease mechanical pain sensitivity and reduce inflammatory markers, such as Substance P, CGRP, and pro-inflammatory cytokines like IL-6 and TNF-α. They can even improve restricted locomotor activity and reduce anxiety in animal models of chronic pain. This points to a future where potentially gentler, non-hallucinogenic options could also harness ibogaine’s neurobiological benefits.

The potential implications extend far beyond a single case. Think about conditions like fibromyalgia, with its widespread pain, fatigue, and cognitive difficulties. Ibogaine’s ability to influence neurotrophic factors, calm NMDA receptors, and reduce inflammation could directly address the pathways implicated in such chronic, diffuse pain syndromes.

For clients struggling with both chronic pain and opioid dependence, ibogaine offers a unique advantage. It can significantly lower opioid tolerance, allowing for a reduction or even cessation of medication while simultaneously improving pain control. It essentially helps restore natural opioid signaling through its sigma-2 receptor affinity, breaking the cycle of both dependence and unmanaged pain. We've seen clients successfully manage hydromorphone, oxycodone, and morphine dependence using ibogaine microdosing protocols for pain.

At Iboga Wellness Institute, our protocols for pain management are highly individualized. They often involve an initial flood dose to achieve that profound neurological reset, followed by extended microdosing or saturation protocols to maintain therapeutic noribogaine levels and support the ongoing healing process. It’s about empowering the body and brain to heal, rather than just endlessly suppressing symptoms, offering a unique avenue for those who have exhausted all other conventional options.]]></content:encoded>
      <guid isPermaLink="false">ThePainResetResearchonIbogainesUnprecedentedReliefforChronicNeuropathicPain</guid>
      <pubDate>Thu, 29 Jan 2026 10:05:20 GMT</pubDate>
      <enclosure
        url="https://oimqzyfmglyhljjuboek.supabase.co/storage/v1/object/public/IBoga_Podcast_Files/ThePainResetResearchonIbogainesUnprecedentedReliefforChronicNeuropathicPain.mp3"
        length="12345678"
        type="audio/mpeg" />
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>

  
    <item>
      <title><![CDATA[The Triple-Threat Mechanism—How Ibogaine Attacks Pain Three Ways]]></title>
      <itunes:image href="https://oimqzyfmglyhljjuboek.supabase.co/storage/v1/object/public/IBoga_Podcast_Files/TheTripleThreatMechanismHowIbogaineAttacksPainThreeWays_Episode_Image.jpeg" />
      <description><![CDATA[Stanford University recently treated thirty Special Operations Forces veterans with PTSD using ibogaine therapy. Eighty-eight percent experienced significant symptom reduction. Twenty-six of those thirty veterans got their lives back. This isn't just about managing symptoms; it’s about a profound neurological reset.

That research highlights the remarkable capacity of the brain to heal when given the right tools. Today, we're sharing the story of Michael, a client who found breakthrough healing for chronic pain, a condition often thought to be irreversible.

Let's hear their story.

Michael was a 45-year-old construction worker whose life was derailed by a severe back injury years ago. What started as acute pain morphed into debilitating, chronic neuropathic pain, leaving him unable to work, play with his kids, or even sleep without intense discomfort. He felt his nervous system was constantly on high alert, screaming louder and louder. He tried everything: countless rounds of physical therapy, steroid injections, even briefly considered long-term opioid use before deciding he needed a different path. Nothing offered more than temporary relief, and the underlying pain always returned, often worse. He felt trapped, losing hope that he'd ever get his life back.

One evening, feeling particularly desperate, he was talking with a veteran friend who had found immense relief from PTSD at the Iboga Wellness Institute. Michael's friend mentioned how ibogaine had reset his brain chemistry, describing it as a "neurological transformation." Intrigued by the idea of not just masking pain but actually *healing* at a neurological level, Michael began researching. He discovered Iboga Wellness Institute's approach to chronic pain, which targets pain at three distinct neurological levels simultaneously. This sounded revolutionary compared to anything he had tried.

When Michael arrived at the Iboga Wellness Institute, he was met with a team dedicated to comprehensive safety and support. Every step of the way, from the initial medical screenings to 24/7 cardiac monitoring and magnesium co-administration, he felt truly cared for. During his treatment, he experienced something profound. He described it as his brain finally getting a chance to reset.

His chronic pain wasn't just physical; it was what experts call "wind-up" pain, where the nervous system becomes overly sensitive and literally learns to amplify pain signals. Michael felt this as a constant, overwhelming scream in his body. Ibogaine works as an NMDA receptor antagonist, effectively turning down the volume on those pain signals that had been screaming too loud for too long. For Michael, this meant the intense, unrelenting pressure in his lower back began to subside, replaced by a quiet he hadn't known in years.

But chronic pain isn't just a sensation; it’s also the profound suffering it causes. Ibogaine’s affinity for sigma-2 receptors plays a crucial role here, modulating pain perception at multiple levels in the brain and spinal cord. Michael explained that beyond the physical relief, the emotional weight of his pain, the constant anxiety and despair, also began to lift. Ibogaine addressed not just the sensation of his pain, but the deep suffering it had caused him for years.

Perhaps the most game-changing aspect for Michael was the feeling of actual healing. Ibogaine stimulates the production of Glial-Derived Neurotrophic Factor, or GDNF. This isn't just about blocking signals; it's about repairing and regenerating damaged nerves. Michael had always been told his nerve damage was irreversible, yet after treatment, he felt an undeniable sense of repair. It was as if his body remembered how to heal itself, promoting the kind of nerve regeneration conventional medicine simply cannot offer. He felt that his nerves were truly beginning to mend, confirming that yes, your nerves *can* heal, and ibogaine helped them do it.

Within weeks, Michael’s daily pain, which had consistently registered an 8 out of 10, dropped to a manageable 2. He could walk without a cane, play with his children in the park, and even started doing light work again. Six months later, Michael continues to thrive. He's no longer reliant on daily pain medication. His story exemplifies how ibogaine offers a comprehensive approach, addressing both the acute pain and the chronic sensitization, promoting actual healing where single-mechanism drugs have failed. It truly allowed him to experience neurological transformation, turning his brokenness into a breakthrough.]]></description>
      <content:encoded><![CDATA[Stanford University recently treated thirty Special Operations Forces veterans with PTSD using ibogaine therapy. Eighty-eight percent experienced significant symptom reduction. Twenty-six of those thirty veterans got their lives back. This isn't just about managing symptoms; it’s about a profound neurological reset.

That research highlights the remarkable capacity of the brain to heal when given the right tools. Today, we're sharing the story of Michael, a client who found breakthrough healing for chronic pain, a condition often thought to be irreversible.

Let's hear their story.

Michael was a 45-year-old construction worker whose life was derailed by a severe back injury years ago. What started as acute pain morphed into debilitating, chronic neuropathic pain, leaving him unable to work, play with his kids, or even sleep without intense discomfort. He felt his nervous system was constantly on high alert, screaming louder and louder. He tried everything: countless rounds of physical therapy, steroid injections, even briefly considered long-term opioid use before deciding he needed a different path. Nothing offered more than temporary relief, and the underlying pain always returned, often worse. He felt trapped, losing hope that he'd ever get his life back.

One evening, feeling particularly desperate, he was talking with a veteran friend who had found immense relief from PTSD at the Iboga Wellness Institute. Michael's friend mentioned how ibogaine had reset his brain chemistry, describing it as a "neurological transformation." Intrigued by the idea of not just masking pain but actually *healing* at a neurological level, Michael began researching. He discovered Iboga Wellness Institute's approach to chronic pain, which targets pain at three distinct neurological levels simultaneously. This sounded revolutionary compared to anything he had tried.

When Michael arrived at the Iboga Wellness Institute, he was met with a team dedicated to comprehensive safety and support. Every step of the way, from the initial medical screenings to 24/7 cardiac monitoring and magnesium co-administration, he felt truly cared for. During his treatment, he experienced something profound. He described it as his brain finally getting a chance to reset.

His chronic pain wasn't just physical; it was what experts call "wind-up" pain, where the nervous system becomes overly sensitive and literally learns to amplify pain signals. Michael felt this as a constant, overwhelming scream in his body. Ibogaine works as an NMDA receptor antagonist, effectively turning down the volume on those pain signals that had been screaming too loud for too long. For Michael, this meant the intense, unrelenting pressure in his lower back began to subside, replaced by a quiet he hadn't known in years.

But chronic pain isn't just a sensation; it’s also the profound suffering it causes. Ibogaine’s affinity for sigma-2 receptors plays a crucial role here, modulating pain perception at multiple levels in the brain and spinal cord. Michael explained that beyond the physical relief, the emotional weight of his pain, the constant anxiety and despair, also began to lift. Ibogaine addressed not just the sensation of his pain, but the deep suffering it had caused him for years.

Perhaps the most game-changing aspect for Michael was the feeling of actual healing. Ibogaine stimulates the production of Glial-Derived Neurotrophic Factor, or GDNF. This isn't just about blocking signals; it's about repairing and regenerating damaged nerves. Michael had always been told his nerve damage was irreversible, yet after treatment, he felt an undeniable sense of repair. It was as if his body remembered how to heal itself, promoting the kind of nerve regeneration conventional medicine simply cannot offer. He felt that his nerves were truly beginning to mend, confirming that yes, your nerves *can* heal, and ibogaine helped them do it.

Within weeks, Michael’s daily pain, which had consistently registered an 8 out of 10, dropped to a manageable 2. He could walk without a cane, play with his children in the park, and even started doing light work again. Six months later, Michael continues to thrive. He's no longer reliant on daily pain medication. His story exemplifies how ibogaine offers a comprehensive approach, addressing both the acute pain and the chronic sensitization, promoting actual healing where single-mechanism drugs have failed. It truly allowed him to experience neurological transformation, turning his brokenness into a breakthrough.]]></content:encoded>
      <guid isPermaLink="false">TheTripleThreatMechanismHowIbogaineAttacksPainThreeWays</guid>
      <pubDate>Mon, 02 Feb 2026 16:21:00 GMT</pubDate>
      <enclosure
        url="https://oimqzyfmglyhljjuboek.supabase.co/storage/v1/object/public/IBoga_Podcast_Files/TheTripleThreatMechanismHowIbogaineAttacksPainThreeWays.mp3"
        length="12345678"
        type="audio/mpeg" />
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>

  </channel>
</rss>
